Italian  ||| S:0 E:8 ||| JJ
cancer  ||| S:8 E:15 ||| NN
figures ||| S:15 E:22 ||| NNS
,  ||| S:22 E:24 ||| ,
report  ||| S:24 E:31 ||| NN
2013 ||| S:31 E:35 ||| CD
:  ||| S:35 E:37 ||| :
Multiple  ||| S:37 E:46 ||| NNP
tumours  ||| S:46 E:54 ||| VBD
This  ||| S:54 E:59 ||| DT
collaborative  ||| S:59 E:73 ||| JJ
study ||| S:73 E:78 ||| NN
,  ||| S:78 E:80 ||| ,
based  ||| S:80 E:86 ||| VBN
on  ||| S:86 E:89 ||| IN
data  ||| S:89 E:94 ||| NNS
collected  ||| S:94 E:104 ||| VBN
by  ||| S:104 E:107 ||| IN
the  ||| S:107 E:111 ||| DT
network  ||| S:111 E:119 ||| NN
of  ||| S:119 E:122 ||| IN
Italian  ||| S:122 E:130 ||| JJ
association  ||| S:130 E:142 ||| NN
of  ||| S:142 E:145 ||| IN
cancer  ||| S:145 E:152 ||| NN
registries  ||| S:152 E:163 ||| NNS
( ||| S:163 E:164 ||| -LRB-
AIRTUM ||| S:164 E:170 ||| NNP
) ||| S:170 E:171 ||| -RRB-
,  ||| S:171 E:173 ||| ,
provides  ||| S:173 E:182 ||| VBZ
updated  ||| S:182 E:190 ||| VBN
estimates  ||| S:190 E:200 ||| NNS
on  ||| S:200 E:203 ||| IN
the  ||| S:203 E:207 ||| DT
incidence  ||| S:207 E:217 ||| JJ
risk  ||| S:217 E:222 ||| NN
of  ||| S:222 E:225 ||| IN
multiple  ||| S:225 E:234 ||| JJ
primary  ||| S:234 E:242 ||| JJ
cancer  ||| S:242 E:249 ||| NN
( ||| S:249 E:250 ||| -LRB-
MP ||| S:250 E:252 ||| NNP
) ||| S:252 E:253 ||| -RRB-
.  ||| S:253 E:255 ||| .
The  ||| S:255 E:259 ||| DT
objective  ||| S:259 E:269 ||| NN
is  ||| S:269 E:272 ||| VBZ
to  ||| S:272 E:275 ||| TO
highlight  ||| S:275 E:285 ||| VB
and  ||| S:285 E:289 ||| CC
quantify  ||| S:289 E:298 ||| VB
the  ||| S:298 E:302 ||| DT
bidirectional  ||| S:302 E:316 ||| JJ
associations  ||| S:316 E:329 ||| NNS
between  ||| S:329 E:337 ||| IN
different  ||| S:337 E:347 ||| JJ
oncological  ||| S:347 E:359 ||| JJ
diseases ||| S:359 E:367 ||| NNS
.  ||| S:367 E:369 ||| .
The  ||| S:369 E:373 ||| DT
quantification  ||| S:373 E:388 ||| NN
of  ||| S:388 E:391 ||| IN
the  ||| S:391 E:395 ||| DT
excess  ||| S:395 E:402 ||| NN
or  ||| S:402 E:405 ||| CC
decreased  ||| S:405 E:415 ||| JJ
risk  ||| S:415 E:420 ||| NN
of  ||| S:420 E:423 ||| IN
further  ||| S:423 E:431 ||| JJ
cancers  ||| S:431 E:439 ||| NNS
in  ||| S:439 E:442 ||| IN
cancer  ||| S:442 E:449 ||| NN
patients ||| S:449 E:457 ||| NNS
,  ||| S:457 E:459 ||| ,
in  ||| S:459 E:462 ||| IN
comparison  ||| S:462 E:473 ||| NN
with  ||| S:473 E:478 ||| IN
the  ||| S:478 E:482 ||| DT
general  ||| S:482 E:490 ||| JJ
population ||| S:490 E:500 ||| NN
,  ||| S:500 E:502 ||| ,
may  ||| S:502 E:506 ||| MD
contribute  ||| S:506 E:517 ||| VB
to  ||| S:517 E:520 ||| TO
understand  ||| S:520 E:531 ||| VB
the  ||| S:531 E:535 ||| DT
aetiology  ||| S:535 E:545 ||| NN
of  ||| S:545 E:548 ||| IN
cancer  ||| S:548 E:555 ||| NN
and  ||| S:555 E:559 ||| CC
to  ||| S:559 E:562 ||| TO
address  ||| S:562 E:570 ||| VB
clinical  ||| S:570 E:579 ||| JJ
follow-up ||| S:579 E:588 ||| NN
.  ||| S:588 E:590 ||| .
Data  ||| S:590 E:595 ||| NNS
herein  ||| S:595 E:602 ||| VBP
presented  ||| S:602 E:612 ||| VBN
were  ||| S:612 E:617 ||| VBD
provided  ||| S:617 E:626 ||| VBN
by  ||| S:626 E:629 ||| IN
AIRTUM  ||| S:629 E:636 ||| NNP
population-based  ||| S:636 E:653 ||| JJ
cancer  ||| S:653 E:660 ||| NN
registries ||| S:660 E:670 ||| NN
,  ||| S:670 E:672 ||| ,
which  ||| S:672 E:678 ||| WDT
cover  ||| S:678 E:684 ||| VBP
nowadays  ||| S:684 E:693 ||| RB
48 ||| S:693 E:695 ||| CD
%  ||| S:695 E:697 ||| NN
of  ||| S:697 E:700 ||| IN
the  ||| S:700 E:704 ||| DT
Italian  ||| S:704 E:712 ||| JJ
population ||| S:712 E:722 ||| NN
.  ||| S:722 E:724 ||| .
This  ||| S:724 E:729 ||| DT
monograph  ||| S:729 E:739 ||| NN
utilizes  ||| S:739 E:748 ||| VBD
the  ||| S:748 E:752 ||| DT
AIRTUM  ||| S:752 E:759 ||| NNP
database  ||| S:759 E:768 ||| NN
( ||| S:768 E:769 ||| -LRB-
December  ||| S:769 E:778 ||| NNP
2012 ||| S:778 E:782 ||| CD
) ||| S:782 E:783 ||| -RRB-
,  ||| S:783 E:785 ||| ,
considering  ||| S:785 E:797 ||| VBG
all  ||| S:797 E:801 ||| DT
malignant  ||| S:801 E:811 ||| JJ
cancer  ||| S:811 E:818 ||| NN
cases  ||| S:818 E:824 ||| NNS
diagnosed  ||| S:824 E:834 ||| VBN
between  ||| S:834 E:842 ||| IN
1976  ||| S:842 E:847 ||| CD
and  ||| S:847 E:851 ||| CC
2010 ||| S:851 E:855 ||| CD
.  ||| S:855 E:857 ||| .
All  ||| S:857 E:861 ||| DT
cases  ||| S:861 E:867 ||| NNS
are  ||| S:867 E:871 ||| VBP
coded  ||| S:871 E:877 ||| VBN
according  ||| S:877 E:887 ||| VBG
to  ||| S:887 E:890 ||| TO
ICD-O-3 ||| S:890 E:897 ||| CD
.  ||| S:897 E:899 ||| .
Non-melanoma  ||| S:899 E:912 ||| JJ
skin  ||| S:912 E:917 ||| NN
cancer  ||| S:917 E:924 ||| NN
cases ||| S:924 E:929 ||| NNS
,  ||| S:929 E:931 ||| ,
cases  ||| S:931 E:937 ||| NNS
based  ||| S:937 E:943 ||| VBN
on  ||| S:943 E:946 ||| IN
death  ||| S:946 E:952 ||| NN
certificate  ||| S:952 E:964 ||| NN
only ||| S:964 E:968 ||| RB
,  ||| S:968 E:970 ||| ,
cases  ||| S:970 E:976 ||| NNS
based  ||| S:976 E:982 ||| VBN
on  ||| S:982 E:985 ||| IN
autopsy  ||| S:985 E:993 ||| VBG
only ||| S:993 E:997 ||| RB
,  ||| S:997 E:999 ||| ,
and  ||| S:999 E:1003 ||| CC
cases  ||| S:1003 E:1009 ||| NNS
with  ||| S:1009 E:1014 ||| IN
follow-up  ||| S:1014 E:1024 ||| JJ
time  ||| S:1024 E:1029 ||| NN
equal  ||| S:1029 E:1035 ||| JJ
to  ||| S:1035 E:1038 ||| TO
zero  ||| S:1038 E:1043 ||| CD
were  ||| S:1043 E:1048 ||| VBD
excluded ||| S:1048 E:1056 ||| VBN
.  ||| S:1056 E:1058 ||| .
To  ||| S:1058 E:1061 ||| TO
define  ||| S:1061 E:1068 ||| VB
multiple  ||| S:1068 E:1077 ||| JJ
primaries ||| S:1077 E:1086 ||| NN
,  ||| S:1086 E:1088 ||| ,
IARC-IACR  ||| S:1088 E:1098 ||| JJ
rules  ||| S:1098 E:1104 ||| NNS
were  ||| S:1104 E:1109 ||| VBD
adopted  ||| S:1109 E:1117 ||| VBN
( ||| S:1117 E:1118 ||| -LRB-
http ||| S:1118 E:1122 ||| NN
: ||| S:1122 E:1123 ||| :
-www.iacr.com.fr ||| S:1123 E:1139 ||| CD
/ ||| S:1139 E:1140 ||| CD
MPrules_july2004.pdf ||| S:1140 E:1160 ||| CD
) ||| S:1160 E:1161 ||| -RRB-
.  ||| S:1161 E:1163 ||| .
Data  ||| S:1163 E:1168 ||| NNP
were  ||| S:1168 E:1173 ||| VBD
subjected  ||| S:1173 E:1183 ||| VBN
to  ||| S:1183 E:1186 ||| TO
standard  ||| S:1186 E:1195 ||| JJ
quality  ||| S:1195 E:1203 ||| NN
control  ||| S:1203 E:1211 ||| NN
procedures  ||| S:1211 E:1222 ||| NNS
( ||| S:1222 E:1223 ||| -LRB-
described  ||| S:1223 E:1233 ||| VBN
in  ||| S:1233 E:1236 ||| IN
the  ||| S:1236 E:1240 ||| DT
AIRTUM  ||| S:1240 E:1247 ||| NNP
data  ||| S:1247 E:1252 ||| NN
management  ||| S:1252 E:1263 ||| NN
protocol ||| S:1263 E:1271 ||| NN
)  ||| S:1271 E:1273 ||| -RRB-
and  ||| S:1273 E:1277 ||| CC
specific  ||| S:1277 E:1286 ||| JJ
quality  ||| S:1286 E:1294 ||| NN
control  ||| S:1294 E:1302 ||| NN
checks  ||| S:1302 E:1309 ||| NNS
defined  ||| S:1309 E:1317 ||| VBN
for  ||| S:1317 E:1321 ||| IN
the  ||| S:1321 E:1325 ||| DT
present  ||| S:1325 E:1333 ||| JJ
study ||| S:1333 E:1338 ||| NN
.  ||| S:1338 E:1340 ||| .
A  ||| S:1340 E:1342 ||| DT
cohort  ||| S:1342 E:1349 ||| NN
of  ||| S:1349 E:1352 ||| IN
cancer  ||| S:1352 E:1359 ||| NN
patients  ||| S:1359 E:1368 ||| NNS
was  ||| S:1368 E:1372 ||| VBD
followed  ||| S:1372 E:1381 ||| VBN
over  ||| S:1381 E:1386 ||| IN
time  ||| S:1386 E:1391 ||| NN
from  ||| S:1391 E:1396 ||| IN
first  ||| S:1396 E:1402 ||| JJ
cancer  ||| S:1402 E:1409 ||| NN
diagnosis  ||| S:1409 E:1419 ||| NN
until  ||| S:1419 E:1425 ||| IN
the  ||| S:1425 E:1429 ||| DT
date  ||| S:1429 E:1434 ||| NN
of  ||| S:1434 E:1437 ||| IN
second  ||| S:1437 E:1444 ||| JJ
cancer  ||| S:1444 E:1451 ||| NN
diagnosis ||| S:1451 E:1460 ||| NN
,  ||| S:1460 E:1462 ||| ,
death ||| S:1462 E:1467 ||| NN
,  ||| S:1467 E:1469 ||| ,
or  ||| S:1469 E:1472 ||| CC
the  ||| S:1472 E:1476 ||| DT
end  ||| S:1476 E:1480 ||| NN
of  ||| S:1480 E:1483 ||| IN
follow-up ||| S:1483 E:1492 ||| NNP
,  ||| S:1492 E:1494 ||| ,
to  ||| S:1494 E:1497 ||| TO
evaluate  ||| S:1497 E:1506 ||| VB
whether  ||| S:1506 E:1514 ||| IN
the  ||| S:1514 E:1518 ||| DT
number  ||| S:1518 E:1525 ||| NN
of  ||| S:1525 E:1528 ||| IN
observed  ||| S:1528 E:1537 ||| JJ
second  ||| S:1537 E:1544 ||| JJ
cancer  ||| S:1544 E:1551 ||| NN
cases  ||| S:1551 E:1557 ||| NNS
was  ||| S:1557 E:1561 ||| VBD
greater  ||| S:1561 E:1569 ||| JJR
than  ||| S:1569 E:1574 ||| IN
expected ||| S:1574 E:1582 ||| VBN
.  ||| S:1582 E:1584 ||| .
Person  ||| S:1584 E:1591 ||| NN
years  ||| S:1591 E:1597 ||| NNS
at  ||| S:1597 E:1600 ||| IN
risk  ||| S:1600 E:1605 ||| NN
( ||| S:1605 E:1606 ||| -LRB-
PY ||| S:1606 E:1608 ||| NNP
)  ||| S:1608 E:1610 ||| -RRB-
were  ||| S:1610 E:1615 ||| VBD
computed  ||| S:1615 E:1624 ||| VBN
by  ||| S:1624 E:1627 ||| IN
first  ||| S:1627 E:1633 ||| JJ
cancer  ||| S:1633 E:1640 ||| NN
site ||| S:1640 E:1644 ||| NN
,  ||| S:1644 E:1646 ||| ,
geographic  ||| S:1646 E:1657 ||| JJ
area  ||| S:1657 E:1662 ||| NN
( ||| S:1662 E:1663 ||| -LRB-
North ||| S:1663 E:1668 ||| NNP
,  ||| S:1668 E:1670 ||| ,
Centre ||| S:1670 E:1676 ||| NNP
,  ||| S:1676 E:1678 ||| ,
South  ||| S:1678 E:1684 ||| NNP
and  ||| S:1684 E:1688 ||| CC
Islands ||| S:1688 E:1695 ||| NNP
) ||| S:1695 E:1696 ||| -RRB-
,  ||| S:1696 E:1698 ||| ,
attained  ||| S:1698 E:1707 ||| JJ
age ||| S:1707 E:1710 ||| NN
,  ||| S:1710 E:1712 ||| ,
and  ||| S:1712 E:1716 ||| CC
attained  ||| S:1716 E:1725 ||| JJ
calendar-year  ||| S:1725 E:1739 ||| JJ
group ||| S:1739 E:1744 ||| NN
.  ||| S:1744 E:1746 ||| .
All  ||| S:1746 E:1750 ||| DT
second  ||| S:1750 E:1757 ||| JJ
cancers  ||| S:1757 E:1765 ||| NNS
diagnosed  ||| S:1765 E:1775 ||| VBN
in  ||| S:1775 E:1778 ||| IN
the  ||| S:1778 E:1782 ||| DT
cohort ||| S:1782 E:1788 ||| NN
's  ||| S:1788 E:1791 ||| POS
patients  ||| S:1791 E:1800 ||| NNS
were  ||| S:1800 E:1805 ||| VBD
included  ||| S:1805 E:1814 ||| VBN
in  ||| S:1814 E:1817 ||| IN
the  ||| S:1817 E:1821 ||| DT
observed  ||| S:1821 E:1830 ||| JJ
numbers  ||| S:1830 E:1838 ||| NNS
of  ||| S:1838 E:1841 ||| IN
cases ||| S:1841 E:1846 ||| NNS
.  ||| S:1846 E:1848 ||| .
The  ||| S:1848 E:1852 ||| DT
expected  ||| S:1852 E:1861 ||| JJ
number  ||| S:1861 E:1868 ||| NN
of  ||| S:1868 E:1871 ||| IN
cancer  ||| S:1871 E:1878 ||| NN
cases  ||| S:1878 E:1884 ||| NNS
was  ||| S:1884 E:1888 ||| VBD
computed  ||| S:1888 E:1897 ||| VBN
multiplying  ||| S:1897 E:1909 ||| VBG
the  ||| S:1909 E:1913 ||| DT
accumulated  ||| S:1913 E:1925 ||| JJ
PY  ||| S:1925 E:1928 ||| NN
by  ||| S:1928 E:1931 ||| IN
the  ||| S:1931 E:1935 ||| DT
expected  ||| S:1935 E:1944 ||| JJ
rates ||| S:1944 E:1949 ||| NNS
,  ||| S:1949 E:1951 ||| ,
calculated  ||| S:1951 E:1962 ||| VBN
from  ||| S:1962 E:1967 ||| IN
the  ||| S:1967 E:1971 ||| DT
AIRTUM  ||| S:1971 E:1978 ||| NNP
database  ||| S:1978 E:1987 ||| NN
stratified  ||| S:1987 E:1998 ||| NN
by  ||| S:1998 E:2001 ||| IN
cancer  ||| S:2001 E:2008 ||| NN
site ||| S:2008 E:2012 ||| NN
,  ||| S:2012 E:2014 ||| ,
geographic  ||| S:2014 E:2025 ||| JJ
area ||| S:2025 E:2029 ||| NN
,  ||| S:2029 E:2031 ||| ,
age ||| S:2031 E:2034 ||| NN
,  ||| S:2034 E:2036 ||| ,
and  ||| S:2036 E:2040 ||| CC
calendar-year  ||| S:2040 E:2054 ||| JJ
group ||| S:2054 E:2059 ||| NN
.  ||| S:2059 E:2061 ||| .
The  ||| S:2061 E:2065 ||| DT
Standardized  ||| S:2065 E:2078 ||| NNP
Incidence  ||| S:2078 E:2088 ||| NNP
Ratio  ||| S:2088 E:2094 ||| NNP
( ||| S:2094 E:2095 ||| -LRB-
SIR ||| S:2095 E:2098 ||| NNP
)  ||| S:2098 E:2100 ||| -RRB-
was  ||| S:2100 E:2104 ||| VBD
calculated  ||| S:2104 E:2115 ||| VBN
as  ||| S:2115 E:2118 ||| IN
the  ||| S:2118 E:2122 ||| DT
ratio  ||| S:2122 E:2128 ||| NN
of  ||| S:2128 E:2131 ||| IN
observed  ||| S:2131 E:2140 ||| JJ
to  ||| S:2140 E:2143 ||| TO
expected  ||| S:2143 E:2152 ||| JJ
cancer  ||| S:2152 E:2159 ||| NN
cases ||| S:2159 E:2164 ||| NNS
.  ||| S:2164 E:2166 ||| .
The  ||| S:2166 E:2170 ||| DT
Excess  ||| S:2170 E:2177 ||| NNP
Absolute  ||| S:2177 E:2186 ||| NNP
Risk  ||| S:2186 E:2191 ||| NNP
( ||| S:2191 E:2192 ||| -LRB-
EAR ||| S:2192 E:2195 ||| NNP
)  ||| S:2195 E:2197 ||| -RRB-
beyond  ||| S:2197 E:2204 ||| IN
the  ||| S:2204 E:2208 ||| DT
expected  ||| S:2208 E:2217 ||| JJ
amount  ||| S:2217 E:2224 ||| NN
were  ||| S:2224 E:2229 ||| VBD
calculated  ||| S:2229 E:2240 ||| VBN
subtracting  ||| S:2240 E:2252 ||| VBG
the  ||| S:2252 E:2256 ||| DT
expected  ||| S:2256 E:2265 ||| JJ
number  ||| S:2265 E:2272 ||| NN
of  ||| S:2272 E:2275 ||| IN
subsequent  ||| S:2275 E:2286 ||| JJ
cancers  ||| S:2286 E:2294 ||| NNS
from  ||| S:2294 E:2299 ||| IN
the  ||| S:2299 E:2303 ||| DT
observed  ||| S:2303 E:2312 ||| JJ
number  ||| S:2312 E:2319 ||| NN
of  ||| S:2319 E:2322 ||| IN
cancer  ||| S:2322 E:2329 ||| NN
cases ||| S:2329 E:2334 ||| NNS
;  ||| S:2334 E:2336 ||| :
the  ||| S:2336 E:2340 ||| DT
difference  ||| S:2340 E:2351 ||| NN
was  ||| S:2351 E:2355 ||| VBD
then  ||| S:2355 E:2360 ||| RB
divided  ||| S:2360 E:2368 ||| VBN
by  ||| S:2368 E:2371 ||| IN
the  ||| S:2371 E:2375 ||| DT
PY  ||| S:2375 E:2378 ||| NNP
and  ||| S:2378 E:2382 ||| CC
the  ||| S:2382 E:2386 ||| DT
number  ||| S:2386 E:2393 ||| NN
of  ||| S:2393 E:2396 ||| IN
cancer  ||| S:2396 E:2403 ||| NN
cases  ||| S:2403 E:2409 ||| NNS
in  ||| S:2409 E:2412 ||| IN
excess  ||| S:2412 E:2419 ||| JJ
( ||| S:2419 E:2420 ||| -LRB-
or  ||| S:2420 E:2423 ||| CC
deficit ||| S:2423 E:2430 ||| NN
)  ||| S:2430 E:2432 ||| -RRB-
was  ||| S:2432 E:2436 ||| VBD
expressed  ||| S:2436 E:2446 ||| VBN
per  ||| S:2446 E:2450 ||| IN
1,000  ||| S:2450 E:2456 ||| CD
PY ||| S:2456 E:2458 ||| NNS
.  ||| S:2458 E:2460 ||| .
Confidence  ||| S:2460 E:2471 ||| NN
intervals  ||| S:2471 E:2481 ||| NNS
were  ||| S:2481 E:2486 ||| VBD
stated  ||| S:2486 E:2493 ||| VBN
at  ||| S:2493 E:2496 ||| IN
95 ||| S:2496 E:2498 ||| CD
% ||| S:2498 E:2499 ||| NN
.  ||| S:2499 E:2501 ||| .
The  ||| S:2501 E:2505 ||| DT
two  ||| S:2505 E:2509 ||| CD
months  ||| S:2509 E:2516 ||| NNS
( ||| S:2516 E:2517 ||| -LRB-
60  ||| S:2517 E:2520 ||| CD
days ||| S:2520 E:2524 ||| NNS
)  ||| S:2524 E:2526 ||| -RRB-
after  ||| S:2526 E:2532 ||| IN
first  ||| S:2532 E:2538 ||| JJ
cancer  ||| S:2538 E:2545 ||| NN
diagnosis  ||| S:2545 E:2555 ||| NN
were  ||| S:2555 E:2560 ||| VBD
defined  ||| S:2560 E:2568 ||| VBN
as  ||| S:2568 E:2571 ||| IN
synchronicity  ||| S:2571 E:2585 ||| JJ
period ||| S:2585 E:2591 ||| NN
,  ||| S:2591 E:2593 ||| ,
and  ||| S:2593 E:2597 ||| CC
in  ||| S:2597 E:2600 ||| IN
the  ||| S:2600 E:2604 ||| DT
main  ||| S:2604 E:2609 ||| JJ
analysis  ||| S:2609 E:2618 ||| NN
observed  ||| S:2618 E:2627 ||| VBD
and  ||| S:2627 E:2631 ||| CC
expected  ||| S:2631 E:2640 ||| JJ
cases  ||| S:2640 E:2646 ||| NNS
during  ||| S:2646 E:2653 ||| IN
this  ||| S:2653 E:2658 ||| DT
period  ||| S:2658 E:2665 ||| NN
were  ||| S:2665 E:2670 ||| VBD
excluded ||| S:2670 E:2678 ||| VBN
.  ||| S:2678 E:2680 ||| .
It  ||| S:2680 E:2683 ||| PRP
was  ||| S:2683 E:2687 ||| VBD
estimated  ||| S:2687 E:2697 ||| VBN
the  ||| S:2697 E:2701 ||| DT
excess  ||| S:2701 E:2708 ||| JJ
risk  ||| S:2708 E:2713 ||| NN
in  ||| S:2713 E:2716 ||| IN
the  ||| S:2716 E:2720 ||| DT
period  ||| S:2720 E:2727 ||| NN
after  ||| S:2727 E:2733 ||| IN
first  ||| S:2733 E:2739 ||| JJ
diagnosis  ||| S:2739 E:2749 ||| NN
( ||| S:2749 E:2750 ||| -LRB-
≥  ||| S:2750 E:2752 ||| CD
0  ||| S:2752 E:2754 ||| CD
months ||| S:2754 E:2760 ||| NNS
) ||| S:2760 E:2761 ||| -RRB-
,  ||| S:2761 E:2763 ||| ,
excluding  ||| S:2763 E:2773 ||| VBG
the  ||| S:2773 E:2777 ||| DT
synchronicity  ||| S:2777 E:2791 ||| JJ
period  ||| S:2791 E:2798 ||| NN
( ||| S:2798 E:2799 ||| -LRB-
≥  ||| S:2799 E:2801 ||| CD
2  ||| S:2801 E:2803 ||| CD
months ||| S:2803 E:2809 ||| NNS
) ||| S:2809 E:2810 ||| -RRB-
,  ||| S:2810 E:2812 ||| ,
and  ||| S:2812 E:2816 ||| CC
during  ||| S:2816 E:2823 ||| IN
the  ||| S:2823 E:2827 ||| DT
following  ||| S:2827 E:2837 ||| JJ
periods ||| S:2837 E:2844 ||| NNS
:  ||| S:2844 E:2846 ||| :
2-11 ||| S:2846 E:2850 ||| CD
,  ||| S:2850 E:2852 ||| ,
12-59 ||| S:2852 E:2857 ||| NNP
,  ||| S:2857 E:2859 ||| ,
60-119  ||| S:2859 E:2866 ||| NNP
and  ||| S:2866 E:2870 ||| CC
120  ||| S:2870 E:2874 ||| CD
months  ||| S:2874 E:2881 ||| NNS
after  ||| S:2881 E:2887 ||| IN
diagnosis ||| S:2887 E:2896 ||| NN
.  ||| S:2896 E:2898 ||| .
First-cancer-site-and-gender-specific  ||| S:2898 E:2936 ||| JJ
sheets  ||| S:2936 E:2943 ||| NNS
are  ||| S:2943 E:2947 ||| VBP
presented ||| S:2947 E:2956 ||| VBN
,  ||| S:2956 E:2958 ||| ,
reporting  ||| S:2958 E:2968 ||| VBG
both  ||| S:2968 E:2973 ||| DT
SIRs  ||| S:2973 E:2978 ||| JJ
and  ||| S:2978 E:2982 ||| CC
EARs ||| S:2982 E:2986 ||| JJ
.  ||| S:2986 E:2988 ||| .
For  ||| S:2988 E:2992 ||| IN
5,979,338  ||| S:2992 E:3002 ||| CD
person-years  ||| S:3002 E:3015 ||| JJ
a  ||| S:3015 E:3017 ||| DT
cohort  ||| S:3017 E:3024 ||| NN
of  ||| S:3024 E:3027 ||| IN
1,635,060  ||| S:3027 E:3037 ||| CD
cancer  ||| S:3037 E:3044 ||| NN
patients  ||| S:3044 E:3053 ||| NNS
( ||| S:3053 E:3054 ||| -LRB-
880,361  ||| S:3054 E:3062 ||| CD
males  ||| S:3062 E:3068 ||| NNS
and  ||| S:3068 E:3072 ||| CC
754,699  ||| S:3072 E:3080 ||| CD
females ||| S:3080 E:3087 ||| NNS
)  ||| S:3087 E:3089 ||| -RRB-
diagnosed  ||| S:3089 E:3099 ||| VBD
between  ||| S:3099 E:3107 ||| IN
1976  ||| S:3107 E:3112 ||| CD
and  ||| S:3112 E:3116 ||| CC
2010  ||| S:3116 E:3121 ||| CD
was  ||| S:3121 E:3125 ||| VBD
followed ||| S:3125 E:3133 ||| VBN
.  ||| S:3133 E:3135 ||| .
The  ||| S:3135 E:3139 ||| DT
mean  ||| S:3139 E:3144 ||| JJ
follow-up  ||| S:3144 E:3154 ||| JJ
length  ||| S:3154 E:3161 ||| NN
was  ||| S:3161 E:3165 ||| VBD
14  ||| S:3165 E:3168 ||| CD
years ||| S:3168 E:3173 ||| NNS
.  ||| S:3173 E:3175 ||| .
Overall ||| S:3175 E:3182 ||| RB
,  ||| S:3182 E:3184 ||| ,
85,399  ||| S:3184 E:3191 ||| CD
metachronous  ||| S:3191 E:3204 ||| NNS
( ||| S:3204 E:3205 ||| -LRB-
latency  ||| S:3205 E:3213 ||| CD
≥2  ||| S:3213 E:3216 ||| CD
months ||| S:3216 E:3222 ||| NNS
)  ||| S:3222 E:3224 ||| -RRB-
cancers  ||| S:3224 E:3232 ||| NNS
were  ||| S:3232 E:3237 ||| VBD
observed ||| S:3237 E:3245 ||| VBN
,  ||| S:3245 E:3247 ||| ,
while  ||| S:3247 E:3253 ||| IN
77,813  ||| S:3253 E:3260 ||| NNP
were  ||| S:3260 E:3265 ||| VBD
expected  ||| S:3265 E:3274 ||| VBN
during  ||| S:3274 E:3281 ||| IN
the  ||| S:3281 E:3285 ||| DT
study  ||| S:3285 E:3291 ||| NN
period ||| S:3291 E:3297 ||| NN
:  ||| S:3297 E:3299 ||| :
SIR ||| S:3299 E:3302 ||| NNP
:  ||| S:3302 E:3304 ||| :
1.10  ||| S:3304 E:3309 ||| CD
( ||| S:3309 E:3310 ||| -LRB-
95 ||| S:3310 E:3312 ||| CD
% ||| S:3312 E:3313 ||| NN
CI  ||| S:3313 E:3316 ||| NNP
1.09-1.10 ||| S:3316 E:3325 ||| NNP
) ||| S:3325 E:3326 ||| -RRB-
,  ||| S:3326 E:3328 ||| ,
EAR ||| S:3328 E:3331 ||| NNP
:  ||| S:3331 E:3333 ||| :
1.32  ||| S:3333 E:3338 ||| CD
x  ||| S:3338 E:3340 ||| SYM
1,000  ||| S:3340 E:3346 ||| CD
person-years  ||| S:3346 E:3359 ||| NNS
( ||| S:3359 E:3360 ||| -LRB-
95 ||| S:3360 E:3362 ||| CD
% ||| S:3362 E:3363 ||| NN
CI  ||| S:3363 E:3366 ||| NNP
1.19  ||| S:3366 E:3371 ||| CD
-  ||| S:3371 E:3373 ||| :
1.46 ||| S:3373 E:3377 ||| CD
) ||| S:3377 E:3378 ||| -RRB-
.  ||| S:3378 E:3380 ||| .
The  ||| S:3380 E:3384 ||| DT
SIR  ||| S:3384 E:3388 ||| NNP
was  ||| S:3388 E:3392 ||| VBD
1.08  ||| S:3392 E:3397 ||| CD
( ||| S:3397 E:3398 ||| -LRB-
95 ||| S:3398 E:3400 ||| CD
% ||| S:3400 E:3401 ||| NN
CI  ||| S:3401 E:3404 ||| NNP
1.08-1.09 ||| S:3404 E:3413 ||| NNP
)  ||| S:3413 E:3415 ||| -RRB-
for  ||| S:3415 E:3419 ||| IN
men  ||| S:3419 E:3423 ||| NNS
( ||| S:3423 E:3424 ||| -LRB-
54,518  ||| S:3424 E:3431 ||| NNP
observed  ||| S:3431 E:3440 ||| VBD
and  ||| S:3440 E:3444 ||| CC
50,260  ||| S:3444 E:3451 ||| RB
expected ||| S:3451 E:3459 ||| VBN
)  ||| S:3459 E:3461 ||| -RRB-
and  ||| S:3461 E:3465 ||| CC
1.12  ||| S:3465 E:3470 ||| CD
( ||| S:3470 E:3471 ||| -LRB-
95 ||| S:3471 E:3473 ||| CD
% ||| S:3473 E:3474 ||| NN
CI  ||| S:3474 E:3477 ||| NNP
1.11-1.13 ||| S:3477 E:3486 ||| NNP
)  ||| S:3486 E:3488 ||| -RRB-
for  ||| S:3488 E:3492 ||| IN
women  ||| S:3492 E:3498 ||| NNS
( ||| S:3498 E:3499 ||| -LRB-
30,881 ||| S:3499 E:3505 ||| CD
/ ||| S:3505 E:3506 ||| CD
27,553 ||| S:3506 E:3512 ||| CD
) ||| S:3512 E:3513 ||| -RRB-
,  ||| S:3513 E:3515 ||| ,
and  ||| S:3515 E:3519 ||| CC
the  ||| S:3519 E:3523 ||| DT
EAR  ||| S:3523 E:3527 ||| NNP
1.61  ||| S:3527 E:3532 ||| NNP
( ||| S:3532 E:3533 ||| -LRB-
95 ||| S:3533 E:3535 ||| CD
% ||| S:3535 E:3536 ||| NN
CI  ||| S:3536 E:3539 ||| NNP
1.37-1.84 ||| S:3539 E:3548 ||| NNP
)  ||| S:3548 E:3550 ||| -RRB-
and  ||| S:3550 E:3554 ||| CC
1.08  ||| S:3554 E:3559 ||| CD
x  ||| S:3559 E:3561 ||| SYM
1,000  ||| S:3561 E:3567 ||| CD
person-years  ||| S:3567 E:3580 ||| NNS
( ||| S:3580 E:3581 ||| -LRB-
95 ||| S:3581 E:3583 ||| CD
% ||| S:3583 E:3584 ||| NN
CI  ||| S:3584 E:3587 ||| NNP
0.93-1.24 ||| S:3587 E:3596 ||| NNP
) ||| S:3596 E:3597 ||| -RRB-
,  ||| S:3597 E:3599 ||| ,
respectively.Moreover ||| S:3599 E:3620 ||| NNP
,  ||| S:3620 E:3622 ||| ,
during  ||| S:3622 E:3629 ||| IN
the  ||| S:3629 E:3633 ||| DT
first  ||| S:3633 E:3639 ||| JJ
two  ||| S:3639 E:3643 ||| CD
months  ||| S:3643 E:3650 ||| NNS
after  ||| S:3650 E:3656 ||| IN
first  ||| S:3656 E:3662 ||| JJ
cancer  ||| S:3662 E:3669 ||| NN
diagnosis  ||| S:3669 E:3679 ||| NN
( ||| S:3679 E:3680 ||| -LRB-
synchronous  ||| S:3680 E:3692 ||| JJ
period ||| S:3692 E:3698 ||| NN
)  ||| S:3698 E:3700 ||| -RRB-
14,807  ||| S:3700 E:3707 ||| CD
cancers  ||| S:3707 E:3715 ||| NNS
were  ||| S:3715 E:3720 ||| VBD
observed  ||| S:3720 E:3729 ||| VBN
while  ||| S:3729 E:3735 ||| IN
3,536  ||| S:3735 E:3741 ||| NNP
were  ||| S:3741 E:3746 ||| VBD
expected  ||| S:3746 E:3755 ||| VBN
( ||| S:3755 E:3756 ||| -LRB-
SIR ||| S:3756 E:3759 ||| NNP
:  ||| S:3759 E:3761 ||| :
4.16 ||| S:3761 E:3765 ||| CD
;  ||| S:3765 E:3767 ||| :
95 ||| S:3767 E:3769 ||| CD
% ||| S:3769 E:3770 ||| NN
CI  ||| S:3770 E:3773 ||| NNP
4.09-4.22 ||| S:3773 E:3782 ||| NNP
) ||| S:3782 E:3783 ||| -RRB-
;  ||| S:3783 E:3785 ||| :
the  ||| S:3785 E:3789 ||| DT
SIR  ||| S:3789 E:3793 ||| NNP
was  ||| S:3793 E:3797 ||| VBD
4.08  ||| S:3797 E:3802 ||| CD
( ||| S:3802 E:3803 ||| -LRB-
95 ||| S:3803 E:3805 ||| CD
% ||| S:3805 E:3806 ||| NN
CI  ||| S:3806 E:3809 ||| NNP
4.00-4.16 ||| S:3809 E:3818 ||| NNP
)  ||| S:3818 E:3820 ||| -RRB-
for  ||| S:3820 E:3824 ||| IN
men  ||| S:3824 E:3828 ||| NNS
and  ||| S:3828 E:3832 ||| CC
4.32  ||| S:3832 E:3837 ||| CD
( ||| S:3837 E:3838 ||| -LRB-
95 ||| S:3838 E:3840 ||| CD
% ||| S:3840 E:3841 ||| NN
CI  ||| S:3841 E:3844 ||| NNP
4.20-4.45 ||| S:3844 E:3853 ||| NNP
)  ||| S:3853 E:3855 ||| -RRB-
for  ||| S:3855 E:3859 ||| IN
women.The  ||| S:3859 E:3869 ||| CD
mean  ||| S:3869 E:3874 ||| JJ
age  ||| S:3874 E:3878 ||| NN
of  ||| S:3878 E:3881 ||| IN
patients  ||| S:3881 E:3890 ||| NNS
at  ||| S:3890 E:3893 ||| IN
first  ||| S:3893 E:3899 ||| JJ
cancer  ||| S:3899 E:3906 ||| NN
diagnosis  ||| S:3906 E:3916 ||| NN
was  ||| S:3916 E:3920 ||| VBD
67.0  ||| S:3920 E:3925 ||| CD
years  ||| S:3925 E:3931 ||| NNS
among  ||| S:3931 E:3937 ||| IN
males  ||| S:3937 E:3943 ||| NNS
and  ||| S:3943 E:3947 ||| CC
65.8  ||| S:3947 E:3952 ||| CD
among  ||| S:3952 E:3958 ||| IN
females.The  ||| S:3958 E:3970 ||| CD
risk  ||| S:3970 E:3975 ||| NN
of  ||| S:3975 E:3978 ||| IN
MP  ||| S:3978 E:3981 ||| NNP
was  ||| S:3981 E:3985 ||| VBD
related  ||| S:3985 E:3993 ||| VBN
to  ||| S:3993 E:3996 ||| TO
age  ||| S:3996 E:4000 ||| NN
being  ||| S:4000 E:4006 ||| VBG
higher  ||| S:4006 E:4013 ||| JJR
for  ||| S:4013 E:4017 ||| IN
younger  ||| S:4017 E:4025 ||| JJR
patients  ||| S:4025 E:4034 ||| NNS
and  ||| S:4034 E:4038 ||| CC
lower  ||| S:4038 E:4044 ||| JJR
for  ||| S:4044 E:4048 ||| IN
older  ||| S:4048 E:4054 ||| JJR
ones ||| S:4054 E:4058 ||| NNS
.  ||| S:4058 E:4060 ||| .
In  ||| S:4060 E:4063 ||| IN
relation  ||| S:4063 E:4072 ||| NN
to  ||| S:4072 E:4075 ||| TO
the  ||| S:4075 E:4079 ||| DT
time  ||| S:4079 E:4084 ||| NN
of  ||| S:4084 E:4087 ||| IN
first  ||| S:4087 E:4093 ||| JJ
cancer  ||| S:4093 E:4100 ||| NN
diagnosis ||| S:4100 E:4109 ||| NN
,  ||| S:4109 E:4111 ||| ,
the  ||| S:4111 E:4115 ||| DT
SIR  ||| S:4115 E:4119 ||| NNP
was  ||| S:4119 E:4123 ||| VBD
very  ||| S:4123 E:4128 ||| RB
high  ||| S:4128 E:4133 ||| JJ
at  ||| S:4133 E:4136 ||| IN
the  ||| S:4136 E:4140 ||| DT
beginning  ||| S:4140 E:4150 ||| NN
and  ||| S:4150 E:4154 ||| CC
then  ||| S:4154 E:4159 ||| RB
decreased ||| S:4159 E:4168 ||| VBN
,  ||| S:4168 E:4170 ||| ,
although  ||| S:4170 E:4179 ||| IN
remaining  ||| S:4179 E:4189 ||| VBG
constantly  ||| S:4189 E:4200 ||| RB
over  ||| S:4200 E:4205 ||| IN
1 ||| S:4205 E:4206 ||| CD
,  ||| S:4206 E:4208 ||| ,
and  ||| S:4208 E:4212 ||| CC
then  ||| S:4212 E:4217 ||| RB
rose  ||| S:4217 E:4222 ||| VBD
over  ||| S:4222 E:4227 ||| IN
time ||| S:4227 E:4231 ||| NN
.  ||| S:4231 E:4233 ||| .
No  ||| S:4233 E:4236 ||| DT
strong  ||| S:4236 E:4243 ||| JJ
differences  ||| S:4243 E:4255 ||| NNS
were  ||| S:4255 E:4260 ||| VBD
evident  ||| S:4260 E:4268 ||| JJ
across  ||| S:4268 E:4275 ||| IN
the  ||| S:4275 E:4279 ||| DT
different  ||| S:4279 E:4289 ||| JJ
incidence  ||| S:4289 E:4299 ||| NN
periods ||| S:4299 E:4306 ||| NNS
,  ||| S:4306 E:4308 ||| ,
which  ||| S:4308 E:4314 ||| WDT
all  ||| S:4314 E:4318 ||| RB
showed  ||| S:4318 E:4325 ||| VBD
an  ||| S:4325 E:4328 ||| DT
increased  ||| S:4328 E:4338 ||| JJ
MP  ||| S:4338 E:4341 ||| NNP
risk.Women  ||| S:4341 E:4352 ||| NNP
had  ||| S:4352 E:4356 ||| VBD
higher  ||| S:4356 E:4363 ||| JJR
SIRs  ||| S:4363 E:4368 ||| NN
than  ||| S:4368 E:4373 ||| IN
expected  ||| S:4373 E:4382 ||| VBN
for  ||| S:4382 E:4386 ||| IN
18  ||| S:4386 E:4389 ||| CD
cancer  ||| S:4389 E:4396 ||| NN
sites ||| S:4396 E:4401 ||| NNS
,  ||| S:4401 E:4403 ||| ,
men  ||| S:4403 E:4407 ||| NNS
for  ||| S:4407 E:4411 ||| IN
12 ||| S:4411 E:4413 ||| CD
.  ||| S:4413 E:4415 ||| .
The  ||| S:4415 E:4419 ||| DT
statistically  ||| S:4419 E:4433 ||| NN
significantly  ||| S:4433 E:4447 ||| RB
SIRs  ||| S:4447 E:4452 ||| JJ
lower  ||| S:4452 E:4458 ||| JJR
than  ||| S:4458 E:4463 ||| IN
1  ||| S:4463 E:4465 ||| CD
were  ||| S:4465 E:4470 ||| VBD
2  ||| S:4470 E:4472 ||| CD
and  ||| S:4472 E:4476 ||| CC
8 ||| S:4476 E:4477 ||| CD
,  ||| S:4477 E:4479 ||| ,
respectively ||| S:4479 E:4491 ||| RB
.  ||| S:4491 E:4493 ||| .
Increased  ||| S:4493 E:4503 ||| VBN
overall  ||| S:4503 E:4511 ||| JJ
MP  ||| S:4511 E:4514 ||| NNP
risk  ||| S:4514 E:4519 ||| NN
was  ||| S:4519 E:4523 ||| VBD
observed  ||| S:4523 E:4532 ||| VBN
for  ||| S:4532 E:4536 ||| IN
patients  ||| S:4536 E:4545 ||| NNS
of  ||| S:4545 E:4548 ||| IN
both  ||| S:4548 E:4553 ||| DT
sexes  ||| S:4553 E:4559 ||| NN
with  ||| S:4559 E:4564 ||| IN
a  ||| S:4564 E:4566 ||| DT
first  ||| S:4566 E:4572 ||| JJ
primary  ||| S:4572 E:4580 ||| NN
in  ||| S:4580 E:4583 ||| IN
the  ||| S:4583 E:4587 ||| DT
oral  ||| S:4587 E:4592 ||| JJ
cavity  ||| S:4592 E:4599 ||| NNS
( ||| S:4599 E:4600 ||| -LRB-
SIR  ||| S:4600 E:4604 ||| NNP
men ||| S:4604 E:4607 ||| NNS
:  ||| S:4607 E:4609 ||| :
1.93 ||| S:4609 E:4613 ||| CD
;  ||| S:4613 E:4615 ||| :
SIR  ||| S:4615 E:4619 ||| NNP
women ||| S:4619 E:4624 ||| NNS
:  ||| S:4624 E:4626 ||| :
1.48 ||| S:4626 E:4630 ||| CD
) ||| S:4630 E:4631 ||| -RRB-
,  ||| S:4631 E:4633 ||| ,
pharynx  ||| S:4633 E:4641 ||| NNS
( ||| S:4641 E:4642 ||| -LRB-
SIR  ||| S:4642 E:4646 ||| NNP
men ||| S:4646 E:4649 ||| NNS
:  ||| S:4649 E:4651 ||| :
2.13 ||| S:4651 E:4655 ||| CD
;  ||| S:4655 E:4657 ||| :
SIR  ||| S:4657 E:4661 ||| NNP
women ||| S:4661 E:4666 ||| NNS
:  ||| S:4666 E:4668 ||| :
1.99 ||| S:4668 E:4672 ||| CD
) ||| S:4672 E:4673 ||| -RRB-
,  ||| S:4673 E:4675 ||| ,
larynx  ||| S:4675 E:4682 ||| NNS
( ||| S:4682 E:4683 ||| -LRB-
SIR  ||| S:4683 E:4687 ||| NNP
men ||| S:4687 E:4690 ||| NNS
:  ||| S:4690 E:4692 ||| :
1.57 ||| S:4692 E:4696 ||| CD
;  ||| S:4696 E:4698 ||| :
SIR  ||| S:4698 E:4702 ||| NNP
women ||| S:4702 E:4707 ||| NNS
:  ||| S:4707 E:4709 ||| :
1.79 ||| S:4709 E:4713 ||| CD
) ||| S:4713 E:4714 ||| -RRB-
,  ||| S:4714 E:4716 ||| ,
oesophagus  ||| S:4716 E:4727 ||| NNS
( ||| S:4727 E:4728 ||| -LRB-
SIR  ||| S:4728 E:4732 ||| NNP
men ||| S:4732 E:4735 ||| NNS
:  ||| S:4735 E:4737 ||| :
1.45 ||| S:4737 E:4741 ||| CD
;  ||| S:4741 E:4743 ||| :
SIR  ||| S:4743 E:4747 ||| NNP
women ||| S:4747 E:4752 ||| NNS
:  ||| S:4752 E:4754 ||| :
1.41 ||| S:4754 E:4758 ||| CD
) ||| S:4758 E:4759 ||| -RRB-
,  ||| S:4759 E:4761 ||| ,
lung  ||| S:4761 E:4766 ||| NN
( ||| S:4766 E:4767 ||| -LRB-
SIR  ||| S:4767 E:4771 ||| NNP
men ||| S:4771 E:4774 ||| NNS
:  ||| S:4774 E:4776 ||| :
1.09 ||| S:4776 E:4780 ||| CD
;  ||| S:4780 E:4782 ||| :
SIR  ||| S:4782 E:4786 ||| NNP
women ||| S:4786 E:4791 ||| NNS
:  ||| S:4791 E:4793 ||| :
1.13 ||| S:4793 E:4797 ||| CD
) ||| S:4797 E:4798 ||| -RRB-
,  ||| S:4798 E:4800 ||| ,
kidney  ||| S:4800 E:4807 ||| NN
( ||| S:4807 E:4808 ||| -LRB-
SIR  ||| S:4808 E:4812 ||| NNP
men ||| S:4812 E:4815 ||| NNS
:  ||| S:4815 E:4817 ||| :
1.14 ||| S:4817 E:4821 ||| CD
;  ||| S:4821 E:4823 ||| :
SIR  ||| S:4823 E:4827 ||| NNP
women ||| S:4827 E:4832 ||| NNS
:  ||| S:4832 E:4834 ||| :
1.15 ||| S:4834 E:4838 ||| CD
) ||| S:4838 E:4839 ||| -RRB-
,  ||| S:4839 E:4841 ||| ,
urinary  ||| S:4841 E:4849 ||| JJ
bladder  ||| S:4849 E:4857 ||| NN
( ||| S:4857 E:4858 ||| -LRB-
SIR  ||| S:4858 E:4862 ||| NNP
men ||| S:4862 E:4865 ||| NNS
:  ||| S:4865 E:4867 ||| :
1.29 ||| S:4867 E:4871 ||| CD
;  ||| S:4871 E:4873 ||| :
SIR  ||| S:4873 E:4877 ||| NNP
women ||| S:4877 E:4882 ||| NNS
:  ||| S:4882 E:4884 ||| :
1.22 ||| S:4884 E:4888 ||| CD
) ||| S:4888 E:4889 ||| -RRB-
,  ||| S:4889 E:4891 ||| ,
thyroid  ||| S:4891 E:4899 ||| NNS
( ||| S:4899 E:4900 ||| -LRB-
SIR ||| S:4900 E:4903 ||| NNP
:  ||| S:4903 E:4905 ||| :
1.22  ||| S:4905 E:4910 ||| CD
in  ||| S:4910 E:4913 ||| IN
both  ||| S:4913 E:4918 ||| DT
sexes ||| S:4918 E:4923 ||| NN
) ||| S:4923 E:4924 ||| -RRB-
,  ||| S:4924 E:4926 ||| ,
Hodgkin  ||| S:4926 E:4934 ||| NNP
lymphoma  ||| S:4934 E:4943 ||| NNS
( ||| S:4943 E:4944 ||| -LRB-
SIR  ||| S:4944 E:4948 ||| NNP
men ||| S:4948 E:4951 ||| NNS
:  ||| S:4951 E:4953 ||| :
1.59 ||| S:4953 E:4957 ||| CD
;  ||| S:4957 E:4959 ||| :
SIR  ||| S:4959 E:4963 ||| NNP
women ||| S:4963 E:4968 ||| NNS
:  ||| S:4968 E:4970 ||| :
1.94 ||| S:4970 E:4974 ||| CD
) ||| S:4974 E:4975 ||| -RRB-
,  ||| S:4975 E:4977 ||| ,
and  ||| S:4977 E:4981 ||| CC
non-Hodgkin  ||| S:4981 E:4993 ||| JJ
lymphoma  ||| S:4993 E:5002 ||| NNS
( ||| S:5002 E:5003 ||| -LRB-
SIR  ||| S:5003 E:5007 ||| NNP
men ||| S:5007 E:5010 ||| NNS
:  ||| S:5010 E:5012 ||| :
1.13 ||| S:5012 E:5016 ||| CD
;  ||| S:5016 E:5018 ||| :
SIR  ||| S:5018 E:5022 ||| NNP
women ||| S:5022 E:5027 ||| NNS
:  ||| S:5027 E:5029 ||| :
1.12 ||| S:5029 E:5033 ||| CD
) ||| S:5033 E:5034 ||| -RRB-
,  ||| S:5034 E:5036 ||| ,
and  ||| S:5036 E:5040 ||| CC
for  ||| S:5040 E:5044 ||| IN
the  ||| S:5044 E:5048 ||| DT
heterogeneous  ||| S:5048 E:5062 ||| JJ
group  ||| S:5062 E:5068 ||| NN
other  ||| S:5068 E:5074 ||| JJ
sites  ||| S:5074 E:5080 ||| NNS
( ||| S:5080 E:5081 ||| -LRB-
SIR  ||| S:5081 E:5085 ||| NNP
men ||| S:5085 E:5088 ||| NNS
:  ||| S:5088 E:5090 ||| :
1.09 ||| S:5090 E:5094 ||| CD
;  ||| S:5094 E:5096 ||| :
SIR  ||| S:5096 E:5100 ||| NNP
women ||| S:5100 E:5105 ||| NNS
:  ||| S:5105 E:5107 ||| :
1.07 ||| S:5107 E:5111 ||| CD
) ||| S:5111 E:5112 ||| -RRB-
.  ||| S:5112 E:5114 ||| .
Moreover ||| S:5114 E:5122 ||| RB
,  ||| S:5122 E:5124 ||| ,
men  ||| S:5124 E:5128 ||| NNS
had  ||| S:5128 E:5132 ||| VBD
a  ||| S:5132 E:5134 ||| DT
higher  ||| S:5134 E:5141 ||| JJR
MP  ||| S:5141 E:5144 ||| NNP
risk  ||| S:5144 E:5149 ||| NN
if  ||| S:5149 E:5152 ||| IN
the  ||| S:5152 E:5156 ||| DT
first  ||| S:5156 E:5162 ||| JJ
cancer  ||| S:5162 E:5169 ||| NN
was  ||| S:5169 E:5173 ||| VBD
in  ||| S:5173 E:5176 ||| IN
the  ||| S:5176 E:5180 ||| DT
testis  ||| S:5180 E:5187 ||| NN
( ||| S:5187 E:5188 ||| -LRB-
SIR ||| S:5188 E:5191 ||| NNP
:  ||| S:5191 E:5193 ||| :
1.24 ||| S:5193 E:5197 ||| CD
) ||| S:5197 E:5198 ||| -RRB-
,  ||| S:5198 E:5200 ||| ,
while  ||| S:5200 E:5206 ||| IN
the  ||| S:5206 E:5210 ||| DT
same  ||| S:5210 E:5215 ||| JJ
was  ||| S:5215 E:5219 ||| VBD
true  ||| S:5219 E:5224 ||| JJ
for  ||| S:5224 E:5228 ||| IN
women  ||| S:5228 E:5234 ||| NNS
with  ||| S:5234 E:5239 ||| IN
gallbladder  ||| S:5239 E:5251 ||| NNS
( ||| S:5251 E:5252 ||| -LRB-
SIR ||| S:5252 E:5255 ||| NNP
:  ||| S:5255 E:5257 ||| :
1.21 ||| S:5257 E:5261 ||| CD
) ||| S:5261 E:5262 ||| -RRB-
,  ||| S:5262 E:5264 ||| ,
skin  ||| S:5264 E:5269 ||| NN
melanoma  ||| S:5269 E:5278 ||| NNS
( ||| S:5278 E:5279 ||| -LRB-
SIR ||| S:5279 E:5282 ||| NNP
:  ||| S:5282 E:5284 ||| :
1.17 ||| S:5284 E:5288 ||| CD
) ||| S:5288 E:5289 ||| -RRB-
,  ||| S:5289 E:5291 ||| ,
bone  ||| S:5291 E:5296 ||| NN
( ||| S:5296 E:5297 ||| -LRB-
SIR ||| S:5297 E:5300 ||| NNP
:  ||| S:5300 E:5302 ||| :
1.41 ||| S:5302 E:5306 ||| CD
) ||| S:5306 E:5307 ||| -RRB-
,  ||| S:5307 E:5309 ||| ,
breast  ||| S:5309 E:5316 ||| NN
( ||| S:5316 E:5317 ||| -LRB-
SIR ||| S:5317 E:5320 ||| NNP
:  ||| S:5320 E:5322 ||| :
1.12 ||| S:5322 E:5326 ||| CD
) ||| S:5326 E:5327 ||| -RRB-
,  ||| S:5327 E:5329 ||| ,
cervix  ||| S:5329 E:5336 ||| FW
uteri  ||| S:5336 E:5342 ||| FW
( ||| S:5342 E:5343 ||| -LRB-
SIR ||| S:5343 E:5346 ||| NNP
:  ||| S:5346 E:5348 ||| :
1.23 ||| S:5348 E:5352 ||| CD
)  ||| S:5352 E:5354 ||| -RRB-
and  ||| S:5354 E:5358 ||| CC
corpus  ||| S:5358 E:5365 ||| JJ
uteri  ||| S:5365 E:5371 ||| NNS
( ||| S:5371 E:5372 ||| -LRB-
SIR ||| S:5372 E:5375 ||| NNP
:  ||| S:5375 E:5377 ||| :
1.23 ||| S:5377 E:5381 ||| CD
) ||| S:5381 E:5382 ||| -RRB-
,  ||| S:5382 E:5384 ||| ,
and  ||| S:5384 E:5388 ||| CC
ovarian  ||| S:5388 E:5396 ||| JJ
cancer  ||| S:5396 E:5403 ||| NN
( ||| S:5403 E:5404 ||| -LRB-
SIR ||| S:5404 E:5407 ||| NNP
:  ||| S:5407 E:5409 ||| :
1.18 ||| S:5409 E:5413 ||| CD
) ||| S:5413 E:5414 ||| -RRB-
.  ||| S:5414 E:5416 ||| .
On  ||| S:5416 E:5419 ||| IN
the  ||| S:5419 E:5423 ||| DT
contrary ||| S:5423 E:5431 ||| NN
,  ||| S:5431 E:5433 ||| ,
a  ||| S:5433 E:5435 ||| DT
first  ||| S:5435 E:5441 ||| JJ
liver  ||| S:5441 E:5447 ||| NN
or  ||| S:5447 E:5450 ||| CC
pancreas  ||| S:5450 E:5459 ||| JJ
cancer  ||| S:5459 E:5466 ||| NN
were  ||| S:5466 E:5471 ||| VBD
associated  ||| S:5471 E:5482 ||| VBN
with  ||| S:5482 E:5487 ||| IN
a  ||| S:5487 E:5489 ||| DT
decreased  ||| S:5489 E:5499 ||| JJ
MP  ||| S:5499 E:5502 ||| NNP
risk  ||| S:5502 E:5507 ||| NN
in  ||| S:5507 E:5510 ||| IN
both  ||| S:5510 E:5515 ||| DT
sexes  ||| S:5515 E:5521 ||| NNS
( ||| S:5521 E:5522 ||| -LRB-
liver  ||| S:5522 E:5528 ||| UH
SIR ||| S:5528 E:5531 ||| UH
:  ||| S:5531 E:5533 ||| :
0.86  ||| S:5533 E:5538 ||| CD
and  ||| S:5538 E:5542 ||| CC
0.81  ||| S:5542 E:5547 ||| CD
for  ||| S:5547 E:5551 ||| IN
men  ||| S:5551 E:5555 ||| NNS
and  ||| S:5555 E:5559 ||| CC
women ||| S:5559 E:5564 ||| NNS
,  ||| S:5564 E:5566 ||| ,
respectively ||| S:5566 E:5578 ||| RB
;  ||| S:5578 E:5580 ||| :
pancreas  ||| S:5580 E:5589 ||| JJ
SIR ||| S:5589 E:5592 ||| NNP
:  ||| S:5592 E:5594 ||| :
0.70  ||| S:5594 E:5599 ||| CD
and  ||| S:5599 E:5603 ||| CC
0.78  ||| S:5603 E:5608 ||| CD
for  ||| S:5608 E:5612 ||| IN
men  ||| S:5612 E:5616 ||| NNS
and  ||| S:5616 E:5620 ||| CC
women ||| S:5620 E:5625 ||| NNS
,  ||| S:5625 E:5627 ||| ,
respectively ||| S:5627 E:5639 ||| RB
) ||| S:5639 E:5640 ||| -RRB-
,  ||| S:5640 E:5642 ||| ,
as  ||| S:5642 E:5645 ||| RB
were  ||| S:5645 E:5650 ||| VBD
those  ||| S:5650 E:5656 ||| DT
of  ||| S:5656 E:5659 ||| IN
colon  ||| S:5659 E:5665 ||| NN
( ||| S:5665 E:5666 ||| -LRB-
SIR ||| S:5666 E:5669 ||| NNP
:  ||| S:5669 E:5671 ||| :
0.93 ||| S:5671 E:5675 ||| CD
) ||| S:5675 E:5676 ||| -RRB-
,  ||| S:5676 E:5678 ||| ,
rectum  ||| S:5678 E:5685 ||| NNS
( ||| S:5685 E:5686 ||| -LRB-
SIR ||| S:5686 E:5689 ||| NNP
:  ||| S:5689 E:5691 ||| :
0.83 ||| S:5691 E:5695 ||| CD
) ||| S:5695 E:5696 ||| -RRB-
,  ||| S:5696 E:5698 ||| ,
gallbladder  ||| S:5698 E:5710 ||| NNS
( ||| S:5710 E:5711 ||| -LRB-
SIR ||| S:5711 E:5714 ||| NNP
:  ||| S:5714 E:5716 ||| :
0.80 ||| S:5716 E:5720 ||| CD
) ||| S:5720 E:5721 ||| -RRB-
,  ||| S:5721 E:5723 ||| ,
prostate  ||| S:5723 E:5732 ||| NNS
( ||| S:5732 E:5733 ||| -LRB-
SIR ||| S:5733 E:5736 ||| NNP
:  ||| S:5736 E:5738 ||| :
0.93 ||| S:5738 E:5742 ||| CD
) ||| S:5742 E:5743 ||| -RRB-
,  ||| S:5743 E:5745 ||| ,
mesothelioma  ||| S:5745 E:5758 ||| NNS
( ||| S:5758 E:5759 ||| -LRB-
SIR ||| S:5759 E:5762 ||| NNP
:  ||| S:5762 E:5764 ||| :
0.65 ||| S:5764 E:5768 ||| CD
) ||| S:5768 E:5769 ||| -RRB-
,  ||| S:5769 E:5771 ||| ,
and  ||| S:5771 E:5775 ||| CC
central  ||| S:5775 E:5783 ||| JJ
nervous  ||| S:5783 E:5791 ||| JJ
system  ||| S:5791 E:5798 ||| NN
( ||| S:5798 E:5799 ||| -LRB-
SIR ||| S:5799 E:5802 ||| NNP
:  ||| S:5802 E:5804 ||| :
0.82 ||| S:5804 E:5808 ||| CD
)  ||| S:5808 E:5810 ||| -RRB-
among  ||| S:5810 E:5816 ||| IN
men ||| S:5816 E:5819 ||| NNS
.  ||| S:5819 E:5821 ||| .
Among  ||| S:5821 E:5827 ||| IN
the  ||| S:5827 E:5831 ||| DT
cancers  ||| S:5831 E:5839 ||| NNS
for  ||| S:5839 E:5843 ||| IN
which  ||| S:5843 E:5849 ||| WDT
the  ||| S:5849 E:5853 ||| DT
EAR  ||| S:5853 E:5857 ||| NNP
is  ||| S:5857 E:5860 ||| VBZ
statistically  ||| S:5860 E:5874 ||| RB
significant ||| S:5874 E:5885 ||| JJ
,  ||| S:5885 E:5887 ||| ,
those  ||| S:5887 E:5893 ||| DT
with  ||| S:5893 E:5898 ||| IN
higher  ||| S:5898 E:5905 ||| JJR
Excess  ||| S:5905 E:5912 ||| NNP
Absolute  ||| S:5912 E:5921 ||| NNP
Risk  ||| S:5921 E:5926 ||| NN
of  ||| S:5926 E:5929 ||| IN
MP  ||| S:5929 E:5932 ||| NNP
were  ||| S:5932 E:5937 ||| VBD
those  ||| S:5937 E:5943 ||| DT
of  ||| S:5943 E:5946 ||| IN
the  ||| S:5946 E:5950 ||| DT
oral  ||| S:5950 E:5955 ||| JJ
cavity  ||| S:5955 E:5962 ||| NNS
( ||| S:5962 E:5963 ||| -LRB-
EAR ||| S:5963 E:5966 ||| NNP
:  ||| S:5966 E:5968 ||| :
16.0  ||| S:5968 E:5973 ||| CD
x  ||| S:5973 E:5975 ||| SYM
1,000  ||| S:5975 E:5981 ||| CD
person-years  ||| S:5981 E:5994 ||| NN
in  ||| S:5994 E:5997 ||| IN
men  ||| S:5997 E:6001 ||| NNS
and  ||| S:6001 E:6005 ||| CC
5.4  ||| S:6005 E:6009 ||| CD
in  ||| S:6009 E:6012 ||| IN
women ||| S:6012 E:6017 ||| NNS
) ||| S:6017 E:6018 ||| -RRB-
,  ||| S:6018 E:6020 ||| ,
pharynx  ||| S:6020 E:6028 ||| NNS
( ||| S:6028 E:6029 ||| -LRB-
17.6  ||| S:6029 E:6034 ||| CD
and  ||| S:6034 E:6038 ||| CC
9.1 ||| S:6038 E:6041 ||| CD
) ||| S:6041 E:6042 ||| -RRB-
,  ||| S:6042 E:6044 ||| ,
larynx  ||| S:6044 E:6051 ||| NNS
( ||| S:6051 E:6052 ||| -LRB-
11.4  ||| S:6052 E:6057 ||| CD
and  ||| S:6057 E:6061 ||| CC
8.8 ||| S:6061 E:6064 ||| CD
) ||| S:6064 E:6065 ||| -RRB-
,  ||| S:6065 E:6067 ||| ,
and  ||| S:6067 E:6071 ||| CC
oesophagus  ||| S:6071 E:6082 ||| NNS
( ||| S:6082 E:6083 ||| -LRB-
8.5  ||| S:6083 E:6087 ||| CD
and  ||| S:6087 E:6091 ||| CC
4.8 ||| S:6091 E:6094 ||| CD
) ||| S:6094 E:6095 ||| -RRB-
.  ||| S:6095 E:6097 ||| .
This  ||| S:6097 E:6102 ||| DT
descriptive  ||| S:6102 E:6114 ||| JJ
study  ||| S:6114 E:6120 ||| NN
provides  ||| S:6120 E:6129 ||| VBZ
quantitative  ||| S:6129 E:6142 ||| JJ
information  ||| S:6142 E:6154 ||| NN
on  ||| S:6154 E:6157 ||| IN
the  ||| S:6157 E:6161 ||| DT
risk  ||| S:6161 E:6166 ||| NN
of  ||| S:6166 E:6169 ||| IN
developing  ||| S:6169 E:6180 ||| VBG
a  ||| S:6180 E:6182 ||| DT
second  ||| S:6182 E:6189 ||| JJ
cancer  ||| S:6189 E:6196 ||| NN
in  ||| S:6196 E:6199 ||| IN
an  ||| S:6199 E:6202 ||| DT
Italian  ||| S:6202 E:6210 ||| JJ
population-based  ||| S:6210 E:6227 ||| JJ
cohort  ||| S:6227 E:6234 ||| NN
of  ||| S:6234 E:6237 ||| IN
approximately  ||| S:6237 E:6251 ||| RB
1.65  ||| S:6251 E:6256 ||| CD
million  ||| S:6256 E:6264 ||| CD
cancer  ||| S:6264 E:6271 ||| NN
patients ||| S:6271 E:6279 ||| NNS
,  ||| S:6279 E:6281 ||| ,
compared  ||| S:6281 E:6290 ||| VBN
to  ||| S:6290 E:6293 ||| TO
the  ||| S:6293 E:6297 ||| DT
risk  ||| S:6297 E:6302 ||| NN
of  ||| S:6302 E:6305 ||| IN
the  ||| S:6305 E:6309 ||| DT
general  ||| S:6309 E:6317 ||| JJ
population ||| S:6317 E:6327 ||| NN
.  ||| S:6327 E:6329 ||| .
During  ||| S:6329 E:6336 ||| IN
the  ||| S:6336 E:6340 ||| DT
follow-up  ||| S:6340 E:6350 ||| JJ
time  ||| S:6350 E:6355 ||| NN
( ||| S:6355 E:6356 ||| -LRB-
on  ||| S:6356 E:6359 ||| IN
average  ||| S:6359 E:6367 ||| JJ
14  ||| S:6367 E:6370 ||| CD
years ||| S:6370 E:6375 ||| NNS
)  ||| S:6375 E:6377 ||| -RRB-
cancer  ||| S:6377 E:6384 ||| NN
patients  ||| S:6384 E:6393 ||| NNS
had  ||| S:6393 E:6397 ||| VBD
an  ||| S:6397 E:6400 ||| DT
MP  ||| S:6400 E:6403 ||| NNP
risk  ||| S:6403 E:6408 ||| NN
that  ||| S:6408 E:6413 ||| WDT
was  ||| S:6413 E:6417 ||| VBD
10 ||| S:6417 E:6419 ||| CD
%  ||| S:6419 E:6421 ||| NN
higher  ||| S:6421 E:6428 ||| JJR
in  ||| S:6428 E:6431 ||| IN
comparison  ||| S:6431 E:6442 ||| NN
to  ||| S:6442 E:6445 ||| TO
the  ||| S:6445 E:6449 ||| DT
general  ||| S:6449 E:6457 ||| JJ
population  ||| S:6457 E:6468 ||| NN
and  ||| S:6468 E:6472 ||| CC
an  ||| S:6472 E:6475 ||| DT
Excess  ||| S:6475 E:6482 ||| NNP
Absolute  ||| S:6482 E:6491 ||| NNP
Risk  ||| S:6491 E:6496 ||| NN
of  ||| S:6496 E:6499 ||| IN
1.32  ||| S:6499 E:6504 ||| CD
x  ||| S:6504 E:6506 ||| SYM
1,000  ||| S:6506 E:6512 ||| CD
person-years ||| S:6512 E:6524 ||| NN
.  ||| S:6524 E:6526 ||| .
Study  ||| S:6526 E:6532 ||| NN
of  ||| S:6532 E:6535 ||| IN
MPs  ||| S:6535 E:6539 ||| JJ
and  ||| S:6539 E:6543 ||| CC
their  ||| S:6543 E:6549 ||| PRP$
risk  ||| S:6549 E:6554 ||| NN
measures  ||| S:6554 E:6563 ||| NNS
are  ||| S:6563 E:6567 ||| VBP
dependent  ||| S:6567 E:6577 ||| JJ
on  ||| S:6577 E:6580 ||| IN
methods  ||| S:6580 E:6588 ||| NNS
used  ||| S:6588 E:6593 ||| VBN
in  ||| S:6593 E:6596 ||| IN
the  ||| S:6596 E:6600 ||| DT
calculation ||| S:6600 E:6611 ||| NN
.  ||| S:6611 E:6613 ||| .
The  ||| S:6613 E:6617 ||| DT
definition  ||| S:6617 E:6628 ||| NN
of  ||| S:6628 E:6631 ||| IN
MP  ||| S:6631 E:6634 ||| NNP
is  ||| S:6634 E:6637 ||| VBZ
not  ||| S:6637 E:6641 ||| RB
univocal  ||| S:6641 E:6650 ||| JJ
and  ||| S:6650 E:6654 ||| CC
using  ||| S:6654 E:6660 ||| VBG
different  ||| S:6660 E:6670 ||| JJ
rules  ||| S:6670 E:6676 ||| NNS
can  ||| S:6676 E:6680 ||| MD
greatly  ||| S:6680 E:6688 ||| RB
change  ||| S:6688 E:6695 ||| VB
the  ||| S:6695 E:6699 ||| DT
number  ||| S:6699 E:6706 ||| NN
of  ||| S:6706 E:6709 ||| IN
cancers  ||| S:6709 E:6717 ||| NNS
in  ||| S:6717 E:6720 ||| IN
a  ||| S:6720 E:6722 ||| DT
patient  ||| S:6722 E:6730 ||| NN
with  ||| S:6730 E:6735 ||| IN
MPs ||| S:6735 E:6738 ||| JJ
.  ||| S:6738 E:6740 ||| .
However ||| S:6740 E:6747 ||| RB
,  ||| S:6747 E:6749 ||| ,
the  ||| S:6749 E:6753 ||| DT
AIRTUM  ||| S:6753 E:6760 ||| NNP
cancer  ||| S:6760 E:6767 ||| NN
registries  ||| S:6767 E:6778 ||| RB
adopt  ||| S:6778 E:6784 ||| VB
the  ||| S:6784 E:6788 ||| DT
same  ||| S:6788 E:6793 ||| JJ
recommendations  ||| S:6793 E:6809 ||| NNS
for  ||| S:6809 E:6813 ||| IN
MP  ||| S:6813 E:6816 ||| NNP
definition ||| S:6816 E:6826 ||| NN
.  ||| S:6826 E:6828 ||| .
This  ||| S:6828 E:6833 ||| DT
monograph  ||| S:6833 E:6843 ||| NN
was  ||| S:6843 E:6847 ||| VBD
therefore  ||| S:6847 E:6857 ||| RB
made  ||| S:6857 E:6862 ||| VBN
possible  ||| S:6862 E:6871 ||| JJ
by  ||| S:6871 E:6874 ||| IN
the  ||| S:6874 E:6878 ||| DT
shared  ||| S:6878 E:6885 ||| JJ
rules  ||| S:6885 E:6891 ||| NNS
and  ||| S:6891 E:6895 ||| CC
standards  ||| S:6895 E:6905 ||| NNS
used  ||| S:6905 E:6910 ||| VBN
by  ||| S:6910 E:6913 ||| IN
AIRTUM  ||| S:6913 E:6920 ||| NNP
registries ||| S:6920 E:6930 ||| NN
.  ||| S:6930 E:6932 ||| .
The  ||| S:6932 E:6936 ||| DT
cancer  ||| S:6936 E:6943 ||| NN
site-specific  ||| S:6943 E:6957 ||| JJ
sheets ||| S:6957 E:6963 ||| NNS
,  ||| S:6963 E:6965 ||| ,
which  ||| S:6965 E:6971 ||| WDT
represent  ||| S:6971 E:6981 ||| VBP
the  ||| S:6981 E:6985 ||| DT
core  ||| S:6985 E:6990 ||| NN
of  ||| S:6990 E:6993 ||| IN
the  ||| S:6993 E:6997 ||| DT
monograph ||| S:6997 E:7006 ||| NN
,  ||| S:7006 E:7008 ||| ,
can  ||| S:7008 E:7012 ||| MD
be  ||| S:7012 E:7015 ||| VB
useful  ||| S:7015 E:7022 ||| JJ
to  ||| S:7022 E:7025 ||| TO
highlight  ||| S:7025 E:7035 ||| VB
and  ||| S:7035 E:7039 ||| CC
quantify  ||| S:7039 E:7048 ||| VB
the  ||| S:7048 E:7052 ||| DT
bidirectional  ||| S:7052 E:7066 ||| JJ
associations  ||| S:7066 E:7079 ||| NNS
among  ||| S:7079 E:7085 ||| IN
different  ||| S:7085 E:7095 ||| JJ
diseases  ||| S:7095 E:7104 ||| NNS
and  ||| S:7104 E:7108 ||| CC
therefore  ||| S:7108 E:7118 ||| RB
provide  ||| S:7118 E:7126 ||| VB
indications  ||| S:7126 E:7138 ||| NNS
for  ||| S:7138 E:7142 ||| IN
clinical  ||| S:7142 E:7151 ||| JJ
follow-up ||| S:7151 E:7160 ||| NN
.  ||| S:7160 E:7162 ||| .
Lifestyle  ||| S:7162 E:7172 ||| JJ
changes  ||| S:7172 E:7180 ||| NNS
in  ||| S:7180 E:7183 ||| IN
more  ||| S:7183 E:7188 ||| RBR
healthful  ||| S:7188 E:7198 ||| JJ
directions  ||| S:7198 E:7209 ||| NNS
can  ||| S:7209 E:7213 ||| MD
have  ||| S:7213 E:7218 ||| VB
a  ||| S:7218 E:7220 ||| DT
positive  ||| S:7220 E:7229 ||| JJ
effect  ||| S:7229 E:7236 ||| NN
in  ||| S:7236 E:7239 ||| IN
the  ||| S:7239 E:7243 ||| DT
cancer  ||| S:7243 E:7250 ||| NN
patient  ||| S:7250 E:7258 ||| NN
population  ||| S:7258 E:7269 ||| NN
and  ||| S:7269 E:7273 ||| CC
should  ||| S:7273 E:7280 ||| MD
always  ||| S:7280 E:7287 ||| RB
be  ||| S:7287 E:7290 ||| VB
recommended ||| S:7290 E:7301 ||| VBN
.  ||| S:7301 E:7303 ||| .
